Skip to main content
SpringerLink
Log in

Chemotherapy of Chronic Lymphocytic Leukemia

  • Chapter
Chronic Lymphocytic Leukemia

Part of the book series: Contemporary Hematology ((CH))

  • 196 Accesses

Abstract

Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia in the United States and Europe and accounts for approx 25% of all leukemias in those regions. Patients with CLL are often asymptomatic at presentation, and the disease is discovered on routine examination. The course of the disease is heterogeneous: a subset of patients will have indolent disease, may never require therapy, and may eventually die of unrelated causes; another subset will have aggressive disease and will survive for only a few years despite treatment. In most patients, the disease will have an intermediate clinical behavior, with slowly increasing leukocytosis and progressive lymphadenopathy and organomegaly, and patients will require treatment at some point. (More details on the epidemiology and clinical presentation of CLL are described in other chapters of this textbook).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 1998; 338: 1506–1514.

    Article  PubMed  CAS  Google Scholar 

  2. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists’ Collaborative Group. J Natl Cancer Inst 1999;91:861–868.

    Google Scholar 

  3. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750–1757.

    Article  PubMed  CAS  Google Scholar 

  4. Jaksic B, Brugiatelli M, Krc I, et al. High dose chlorambucil versus Binet’s modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna. Cancer 1997; 79: 2107–2114.

    Article  PubMed  CAS  Google Scholar 

  5. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981; 304: 441–447.

    Article  PubMed  CAS  Google Scholar 

  6. Dedrick RL, Morrison PF. Carcinogenic potency of alkylating agents in rodents and humans. Cancer Res 1992; 52: 2464–2467.

    PubMed  CAS  Google Scholar 

  7. Patapanian H, Graham S, Sambrook PN, et al. The oncogenicity of chlorambucil in rheumatoid arthritis. Br J Rheumatol 1988; 27: 44–47.

    Article  PubMed  CAS  Google Scholar 

  8. Han T, Ezdinli EZ, Shimaoka K, Desai DV. Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia. Cancer 1973; 31: 502–508.

    Article  PubMed  CAS  Google Scholar 

  9. Catovsky DRS, Fooks J, Hamblin TJ. CLL trials in the United Kingdom. The Medical Research Council Trials 1,2 and 3. Leuk Lymphoma 1991;(suppl):105–112.

    Google Scholar 

  10. Pethema SCG. Treatment of chronic lymphocytic leukemia: a preliminary report of Spanish (Pethema) trials. Leuk Lymphoma 1991;(suppl):89–91.

    Google Scholar 

  11. A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. The French Cooperative Group on Chronic Lymphocytic Leukemia. Blood 1990; 75: 1422–1425.

    Google Scholar 

  12. Raphael B, Andersen JW, Silber R, et al. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. J Clin Oncol 1991; 9: 770–776.

    PubMed  CAS  Google Scholar 

  13. Long-term results of the CHOP regimen in stage C chronic lymphocytic leukaemia. French Cooperative Group on Chronic Lymphocytic Leukaemia. Br J Haematol 1989; 73: 334–340.

    Article  Google Scholar 

  14. Is the CHOP regimen a good treatment for advanced CLL? Results from two randomized clinical trials. French Cooperative Group on Chronic Lymphocytic Leukemia. Leuk Lymphoma 1994;13:449–456.

    Google Scholar 

  15. Kimby E MH. Chlorambucil/prednisone versus CHOP in symptomatic chronic lymphocytic leukemias of B-cell type. A randomozed trial. Leuk Lymphoma 1991;(suppl):93–96.

    Google Scholar 

  16. Hansen MM, Birgens H, Christensen BE, et al. CHOP versus chlorambucil + prednisone in chronic lymphocytic leukemia. Leuk Lymphoma 1991;(suppl):97–100.

    Google Scholar 

  17. Kempin S, Lee BJ 3rd, Thaler HT, et al. Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone). Blood 1982; 60: 1110–1121.

    PubMed  CAS  Google Scholar 

  18. Case DC, Jr., Porensky RS, Fanning JP. Combination chemotherapy with the M-2 protocol (BCNU, cyclophosphamide, vincristine, melphalan, and prednisone) for chronic lymphocytic leukemia (stages III and IV). Oncology 1985; 42: 350–353.

    Article  PubMed  Google Scholar 

  19. Keating MJ, Scouros M, Murphy S, et al. Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia. Leukemia 1988; 2: 157–164.

    PubMed  CAS  Google Scholar 

  20. Grever MR, Leiby JM, Kraut EH, et al. Low-dose deoxycoformycin in lymphoid malignancy. J Clin Oncol 1985; 3: 1196–1201.

    PubMed  CAS  Google Scholar 

  21. Dillman RO, Mick R, McIntyre OR. Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia Group B. J Clin Oncol 1989; 7: 433–438.

    PubMed  CAS  Google Scholar 

  22. Vose JM, Cabanillas F, O’Brien S, Dang N, Drapkin R, Foss F. Infectious complications of pentostatin therapy. Oncology (Huntingt) 2000; 14: 41–42.

    CAS  Google Scholar 

  23. Keating MJ, O’Brien S, Kantarjian H, et al. Nucleoside analogs in treatment of chronic lymphocytic leukemia. Leuk Lymphoma 1993; 10: 139–145.

    Article  PubMed  Google Scholar 

  24. Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 1999; 17: 2454–2460.

    PubMed  CAS  Google Scholar 

  25. Waselenko JK, Grever MR, Beer M, Lucas MA, Byrd JC. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabinerefractory B-cell chronic lymphocytic leukemia. Semin Oncol 2000; 27: 44–51.

    PubMed  CAS  Google Scholar 

  26. Weiss MA. A phase I and II study of pentostatin (Nipent) with cyclophosphamide for previously treated patients with chronic lymphocytic leukemia. Semin Oncol 2000; 27: 41–43.

    PubMed  CAS  Google Scholar 

  27. Drapkin R. Pentostatin and rituximab in the treatment of patients with B-cell malignancies. Oncology (Huntingt) 2000; 14: 25–29.

    CAS  Google Scholar 

  28. Robertson LE, Chubb S, Meyn RE, et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2chloro-2’-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine. Blood 1993; 81: 143–50.

    PubMed  CAS  Google Scholar 

  29. Piro LD, Carrera CJ, Beutler E, Carson DA. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 72: 1069–1073.

    PubMed  CAS  Google Scholar 

  30. Juliusson G, Liliemark J. High complete remission rate from 2-chloro-2’-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol 1993; 11: 679–689.

    PubMed  CAS  Google Scholar 

  31. Robak T, Blasinka-Morawiec M, Krykowski E, et al. Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B- cell chronic lymphocytic leukemia. Leuk Lymphoma 1996; 22: 509–514.

    Article  PubMed  CAS  Google Scholar 

  32. Juliusson G, Christiansen I, Hansen MM, et al. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 1996; 14: 2160–2166.

    PubMed  CAS  Google Scholar 

  33. Rai KR. Cladribine for the treatment of hairy cell leukemia and chronic lymphocytic leukemia. Semin Oncol 1998; 25: 19–22.

    PubMed  CAS  Google Scholar 

  34. Robak T, Blonski JZ, Urbanska-Rys H, Blasinska-Morawiec M, Skotnicki AB. 2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger. Leukemia 1999;13:518–523.

    Google Scholar 

  35. Robak T, Blonski JZ, Kasznicki M, et al. Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia–updated results of the multicentre study of 378 patients. Br J Haematol 2000; 108: 357–368.

    Article  PubMed  CAS  Google Scholar 

  36. Juliusson G, Elmhorn-Rosenborg A, Liliemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1992; 327: 1056–1061.

    Article  PubMed  CAS  Google Scholar 

  37. O’ Brien S, Kantarjian H, Estey E, et al. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med 1994; 330: 319–322.

    Article  PubMed  Google Scholar 

  38. Saven A, Lemon RH, Piro LD. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1993; 328: 812–813.

    Article  PubMed  CAS  Google Scholar 

  39. Plunkett W, Gandhi V, Huang P, et al. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol 1993; 20: 2–12.

    PubMed  CAS  Google Scholar 

  40. Huang P, Sandoval A, Van Den Neste E, Keating MJ, Plunkett W. Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia 2000; 14: 1405–1413.

    Article  PubMed  CAS  Google Scholar 

  41. Grever MR, Kopecky KJ, Coltman CA, et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 1988; 30: 457–459.

    PubMed  CAS  Google Scholar 

  42. Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19–25.

    PubMed  CAS  Google Scholar 

  43. Robertson LE, O’Brien S, Kantarjian H, et al. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia 1995; 9: 1444–1449.

    PubMed  CAS  Google Scholar 

  44. O’Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82: 1695–1700.

    PubMed  Google Scholar 

  45. Kemena A, O’Brien S, Kantarjian H, et al. Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule. Leuk Lymphoma 1993; 10: 187–193.

    Article  PubMed  CAS  Google Scholar 

  46. Keating MJ, Smith TL, Lerner S, et al. Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia. Leuk Lymphoma 2000; 37: 71–85.

    Article  PubMed  CAS  Google Scholar 

  47. Sorensen JM, Vena DA, Fallavollita A, Chun HG, Cheson BD. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report. J Clin Oncol 1997; 15: 458–465.

    PubMed  CAS  Google Scholar 

  48. Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996; 347: 1432–1438.

    PubMed  CAS  Google Scholar 

  49. Keating MJ, O’Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998; 92: 1165–1171.

    PubMed  CAS  Google Scholar 

  50. Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001; 98: 2319–2325.

    Article  PubMed  CAS  Google Scholar 

  51. Morrison VA, Rai KR, Peterson BL, et al. Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol 2001; 19: 3611–3621.

    PubMed  CAS  Google Scholar 

  52. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995; 13: 2431–2448.

    PubMed  CAS  Google Scholar 

  53. Cheson BD, Vena DA, Foss FM, Sorensen JM. Neurotoxicity of purine analogs: a review. J Clin Oncol 1994; 12: 2216–2228.

    PubMed  CAS  Google Scholar 

  54. Anaissie EJ, Kontoyiannis DP, O’Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998; 129: 559–566.

    PubMed  CAS  Google Scholar 

  55. Cheson BD, Frame JN, Vena D, Quashu N, Sorensen JM. Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. J Clin Oncol 1998; 16: 2313–2320.

    PubMed  CAS  Google Scholar 

  56. Myint H, Copplestone JA, Orchard J, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995; 91: 341–344.

    Article  PubMed  CAS  Google Scholar 

  57. Foran JM, Oscier D, Orchard J, et al. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with “low-grade” non-Hodgkin’s lymphoma and B-cell chronic lymphocytic leukemia. J Clin Oncol 1999; 17: 1574–1579.

    PubMed  CAS  Google Scholar 

  58. Boogaerts MA, Van Hoof A, Catovsky D, et al. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 4252–4258.

    PubMed  CAS  Google Scholar 

  59. Robertson LE, O’Brien S, Kantarjian H, et al. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. Leukemia 1995; 9: 943–945.

    PubMed  CAS  Google Scholar 

  60. O’Brien S. Clinical challenges in chronic lymphocytic leukemia. Semin Hematol 1998; 35: 22–26.

    PubMed  Google Scholar 

  61. Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 1999; 94: 2836–28343.

    PubMed  CAS  Google Scholar 

  62. Koehl U LL, Nowak B, Ruiz van Haperen V, Kornhuber D, Schwabe D, O’Brien S, Keating M, Plunkett W, Yang LW. Fludarabine and cyclophosphamide: synergistic cytotoxicity associated with inhibition of interstrand cross-link removal. Proc Am Assoc Cancer Res 1997; 38: 10.

    Google Scholar 

  63. Elias L, Stock-Novack D, Head DR, et al. A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study. Leukemia 1993; 7: 361–365.

    PubMed  CAS  Google Scholar 

  64. Weiss M, Spiess T, Berman E, Kempin S. Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia. Leukemia 1994; 8: 1290–1293.

    PubMed  CAS  Google Scholar 

  65. Giles FJ, O’ Brien SM, Santini V, et al. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study. Leuk Lymphoma 1999; 36: 57–65.

    Article  PubMed  CAS  Google Scholar 

  66. O’Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 1414–1420.

    PubMed  Google Scholar 

  67. Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 2000; 96: 71–75.

    PubMed  CAS  Google Scholar 

  68. Hallek M, Schmitt B, Wilhelm M, et al. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. Br J Haematol 2001; 114: 342–348.

    Article  PubMed  CAS  Google Scholar 

  69. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833.

    PubMed  CAS  Google Scholar 

  70. Nguyen DT, Amess JA, Doughty H, Hendry L, Diamond LW. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin’s lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 1999; 62: 76–82.

    Article  PubMed  CAS  Google Scholar 

  71. Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001; 98: 1326–1331.

    Article  PubMed  CAS  Google Scholar 

  72. O’Brien SM, Thomas D, Freireich EJ, Andreeff M, Giles FJ, Keating MJ. Rituxan has significant activity in patients with CLL. Blood 1999; 94; 603a.

    Google Scholar 

  73. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19: 2153–2164.

    PubMed  CAS  Google Scholar 

  74. Hainsworth JD, Burris HA, 3rd, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000; 95: 3052–306.

    PubMed  CAS  Google Scholar 

  75. Thomas DA O’Brien S, Giles FJ, et al. Single agent rituxan in early stage chronic lymphocytic leukemia (CLL). Blood 2001; 98: 364a.

    Google Scholar 

  76. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94: 2217–2224.

    PubMed  CAS  Google Scholar 

  77. Yang H, Rosove MH, Figlin RA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Am J Hematol 1999; 62: 247–250.

    Article  PubMed  CAS  Google Scholar 

  78. Garcia Manero G, O’Brien S, Cortes J, et al. Update of results of the combination of fludarabine, cyclophosphamide and rituxan for previously treated patients with chronic lymphocytic leukemia (CLL). Blood 2001; 98: 633a.

    Google Scholar 

  79. Wierda W, O’Brien S, Albitar M, et al. Combined fludarabine, cyclophosphamide, and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia (CLL). Blood 2001; 98: 771a.

    Google Scholar 

  80. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003; 101: 6–14.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Alessandra Ferrajoli MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael J. Keating MB, BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Susan M. O’Brien MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Section of Hematology/Oncology, Veterans Affairs Medical Center, Augusta, GA, USA

    Guy B. Faguet MD

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Ferrajoli, A., Keating, M.J., O’Brien, S.M. (2004). Chemotherapy of Chronic Lymphocytic Leukemia. In: Faguet, G.B. (eds) Chronic Lymphocytic Leukemia. Contemporary Hematology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-412-2_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-412-2_13

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-355-8

  • Online ISBN: 978-1-59259-412-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation